What Glytec does

Glytec is a Greenville/Atlanta-based healthcare technology company that develops and commercializes GlytecOne, a cloud-based, FDA-cleared platform for inpatient glycemic management. Its core engine, Glucommander, is a Class II Software as a Medical Device that has provided algorithm-based insulin dosing recommendations (IV and subcutaneous) since 2006 with zero recalls, and the platform extends into clinical workflow standardization, performance analytics, and population health intelligence across the care continuum. The company serves 400+ U.S. hospitals and health systems through a direct enterprise sales motion, with the 2026 CMS Hospital Harm eCQM mandate (NQF #3503e and #3533e) acting as a primary demand catalyst. Glytec is a wholly-owned subsidiary of Aseko, Inc., and sells primarily via annual subscription SaaS contracts whose pricing varies by hospital size and footprint, reporting customer outcomes of 6-8x ROI, up to 99.8% reduction in severe hypoglycemia events, and 50+ billion data points processed.

The company is led by President & CEO Patrick F. Cua (appointed 2024) and has raised a visible ~$78M across multiple venture and growth rounds, including a $36M growth investment in July 2025 led by Savitr Capital and Hayfin Capital Management. In March 2026 it announced relocation of global headquarters from Boston to Cobb County, Georgia, with 500 new jobs planned over several years. Strategic partners include Premier (Patient Safety Solutions Agreement), Leapfrog (Partner Advisory Committee), Roche (point-of-care device integration), University Hospitals, and Major Health Partners; the company also holds ISO 13485 and HITRUST CSF certifications and has secured 100+ patents and 100+ clinical publications.

Name

Glytec

Legal name

Glytec, LLC

Website

https://glytec.com

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

51–100 employees

Short description

Glytec is a U.S.-based healthcare technology company that sells GlytecOne, an FDA-cleared, cloud-based glycemic management platform anchored by the Glucommander insulin dosing algorithm, to 400+ hospitals, health systems, and increasingly to health plans and value-based care organizations.

Ownership category

akta.pro rank

Product category

Clinical Decision Support Software

NAICS

Computer Systems Design and Related Services (54151)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators) (HLAHAHAJ)

akta.pro secondary industry

Connected Therapeutics & Smart Drug Delivery Monitoring (HLACAFAL)

Keywords

• Insulin management software
• Glycemic management platform
• FDA-cleared medical software
• Clinical decision support
• Diabetes therapy management

Headquarters

HQ city

Greenville

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

1. SaaS Platform Subscription: Glytec operates as a SaaS healthcare technology company offering subscription-based access to its GlytecOne platform. The platform includes FDA-cleared Glucommander insulin dosing software and Command Center analytics. Revenue is generated through annual licensing agreements with hospitals and health systems, with pricing likely based on hospital size or patient volume.

Pricing tiers

Go-to-market motion2 records

Distribution channels1 record

Marketing channels7 records

Core offering

Glytec develops and sells the GlytecOne unified glycemic management SaaS platform for hospitals and health systems. Its core product is Glucommander, an FDA-cleared Class II Software as a Medical Device that provides algorithm-based IV and SubQ insulin dosing recommendations for hospitalized patients. The platform integrates bi-directionally with Epic, Oracle Health (Cerner), and Meditech EHRs and includes Command Center analytics, performance benchmarking, and CMS eCQM reporting.

Product overview

Glytec offers a unified platform architecture centered on GlytecOne, the first unified glycemic management platform that integrates four pillars: Care Enablement, Decision Support, Performance Insights, and Population Health. The platform's core product is Glucommander, an FDA-cleared Class II Software as a Medical Device providing algorithm-based IV (Glucommander IV) and subcutaneous (Glucommander SubQ) insulin dosing recommendations since 2006. Command Center serves as the clinical data visualization and analytics layer powering both Decision Support and Performance Insights, enabling current patient visibility, structured clinical review, and regulatory-ready eCQM reporting. The Population Health pillar extends enterprise glycemic intelligence to health system leaders and health plan partners. Glytec also offers the CMS Reporting CareKit as a preparation resource for the 2026 CMS mandate. Glytec serves 400+ hospitals and health systems with over 100 patents and 100+ clinical publications validating its outcomes.

Differentiator

Problem solved

Functional benefit

Brands

• GlytecOne: The first unified glycemic management platform that integrates clinical decision support, workflow automation, performance analytics, and enterprise population health intelligence.
• Glucommander
• eGlycemic Management System (eGMS)
• Command Center
• Glucommander IV
• Glucommander SubQ

Products and services

• GlytecOne The first unified glycemic management platform that integrates clinical decision support, workflow automation, performance analytics, and enterprise population health intelligence. Built on four pillars: Care Enablement, Decision Support, Performance Insights, and Population Health. Connects care team members and hospital leaders with the data and tools to deliver safer, more consistent glucose management across the entire health system.
• Glucommander FDA-cleared Class II Software as a Medical Device (SaMD) providing algorithm-based insulin dosing recommendations for hospitalized patients ages 2 and older. Available in two configurations: Glucommander IV for intravenous insulin dosing in acute and critical care settings, and Glucommander SubQ for subcutaneous basal-bolus insulin dosing in non-ICU and transitional care. Clinicians review and confirm all recommendations before administration. Has zero FDA recall record since 2006.
• Command Center Clinical data visualization and analytics platform that provides healthcare professionals and administrators with organized displays of current and historical glycemic management information to support quality improvement, care coordination, and clinical review activities. Receives laboratory values, medication administration data, and clinical information from hospital EHR systems and presents this through dashboards, reports, and trend visualizations. Powers the Decision Support and Performance Insights pillars of GlytecOne.
• Glytec CMS Reporting CareKit A comprehensive resource bundle designed to help hospitals prepare for the 2026 CMS Mandate requiring reporting of severe hypoglycemia (NQF #3503e) and severe hyperglycemia (NQF #3533e) as hospital harm eCQMs. Includes a CMS ruling summary, expert implementation timeline, and a CMS compliance checklist.
• eGlycemic Management System (eGMS) Modularized solution for glycemic management across the care continuum, including Glucommander. Supports both IV and SubQ insulin dosing guidance. Superseded by GlytecOne in 2024 as the unified platform architecture.

Quantifiable outcome

• Up to 99.8% reduction in severe hypoglycemia events
• +9 more outcomes

Named customers6 records

Segments6 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability3 records

Feature7 records

Partnerships

Seven partnerships are on record, tiered core and strategic.

• Advocate HealthcoreStrategic or Co-development PartnerGlytec and Advocate Health Beverly Knight Olson Children's Hospital won the top innovation award at the Society of Critical Care Medicine's Innovation Incubator for clinical evidence supporting software-guided insulin dosing in pediatric diabetic ketoacidosis patients. The study covered 1,372 children treated with Glucommander showing zero mortality. Glytec plans to continue collaboration through additional pediatric research and publications.
• University HospitalscoreStrategic or Co-development PartnerGlytec and University Hospitals forged strategic partnership in 2024 to drive continued improvement in patient care and diabetes management. The partnership focuses on clinical collaboration and evidence development for glycemic management.
• Major Health Partners (MHP)coreStrategic or Co-development PartnerGlytec and Major Health Partners forged strategic partnership in 2024 to drive continued improvement in patient care and diabetes management through Glytec's eGMS technology.
• RochestrategicTechnology or IntegrationGlytec and Roche struck collaboration in 2022 on insulin management diagnostics on handheld point-of-care devices. The partnership enhances interoperability between Roche's diagnostic devices and Glytec's insulin management software.
• CPS Solutions, LLCstrategicImplementation/ SI/ Consulting PartnerGlytec and CPS Solutions, LLC integrated in 2022 to provide evidence-based glycemic management. CPS is a leading provider of enterprise pharmacy solutions to hospitals and health systems.
• Leapfrog GroupstrategicGTM or Marketing PartnerGlytec joined Leapfrog's Partner Advisory Committee in 2024 to enhance patient safety and elevate inpatient diabetes care. The partnership positions Glytec as a preferred solution for Leapfrog member hospitals.
• PremierstrategicGTM or Marketing PartnerGlytec was awarded first Patient Safety Solutions Agreement with Premier in 2021, providing preferred pricing and access to Glytec's eGMS solutions for Premier member hospitals.

Scale indicators9 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Monarch Medical Technologies (EndoTool): Monarch Medical Technologies makes EndoTool, the most direct competitor to Glucommander for hospital-based IV and SubQ insulin dosing. Glytec has published head-to-head clinical data showing 62% fewer severe hypoglycemia ADEs and 47% nursing time savings vs EndoTool, making this the closest comparable peer.
• Voluntis (Aptar Digital Health): Voluntis (now part of Aptar Digital Health) developed Theraxium and other FDA-cleared insulin dose titration software, competing directly with Glucommander in the digital therapeutics and decision support category. Comparable in regulatory pathway (FDA SaMD) and target clinical use case.

Emerging players

• DreaMed Diabetes (now part of LifeScan): DreaMed developed Advisor Pro and other AI-based insulin dosing decision support systems for diabetes management. After LifeScan acquisition, the company is positioned in both hospital and outpatient diabetes decision support, making it an adjacent competitor with similar clinical evidence-based positioning.
• Roche Diabetes Care: Roche is both a current technology partner (Roche-Glytec point-of-care integration) and a broader diabetes management player. The partnership validates interoperability but also positions Roche as a strategic peer that could choose to build or acquire competing dosing capabilities.
• Stanson Health (Premier): Stanson Health, a Premier company, provides clinical decision support solutions that include some glycemic management workflows. As a Premier-affiliated vendor, it competes for some of the same hospital CDS budget that Glytec targets through its Premier partnership.

Broad incumbents

• Epic Systems: Epic is the largest US hospital EHR vendor and a current integration partner of Glytec. Epic includes built-in insulin dosing calculators and weight-based protocols that compete in the same clinical workflow as Glucommander, particularly for hospitals with less complex glycemic needs. Glytec publishes favorable outcomes comparisons vs Epic DIY approaches.
• Oracle Health (Cerner): Oracle Health (formerly Cerner) is a major US hospital EHR vendor and Glytec integration partner. Like Epic, Oracle Health provides embedded clinical decision support that competes at the lower end of glycemic management complexity, though it remains a partner for hospital customers seeking best-of-breed dosing.
• Medtronic (Diabetes Operating Unit): Medtronic operates a major diabetes business including insulin pumps and the MiniMed 780G automated insulin delivery system. While focused on outpatient/closed-loop delivery rather than hospital dosing, Medtronic is a relevant adjacent player in the broader diabetes management technology category and a potential strategic acquirer.
• Dexcom: Dexcom is the dominant US continuous glucose monitoring (CGM) vendor, providing glucose data inputs to hospital glycemic management workflows. While not a dosing competitor, Dexcom's data feeds into Glytec's dosing recommendations and they could partner or compete for hospital diabetes technology budgets.
• Health Catalyst: Health Catalyst is a healthcare analytics and outcomes improvement platform serving US hospitals. Its population health and quality reporting capabilities overlap with Glytec's Performance Insights and Population Health pillars, making it a relevant adjacent competitor for analytics-driven glycemic management budget.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/glytec
• LinkedInlinkedin.com/company/glytec-llc

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles20 records

Funding overview

Funding rounds10 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Glytec